List all clinical trials by discovery date. Accepts regular expressions in search.

GET /trials/
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 5278,
    "next": "http://api.gregory-ms.com/trials/?page=2",
    "previous": null,
    "results": [
        {
            "trial_id": 5051,
            "title": "Unraveling Active Ingredients of Neurorehabilitation: Investigating Cortical Activity During Task-oriented Exercises",
            "summary": "<b>Conditions</b>: Multiple Sclerosis; Healthy Volunteer\n<br /><b>Sponsors</b>: Fondazione Don Carlo Gnocchi Onlus; Università degli Studi of Genova; University of Milan\n<br /><b>Recruiting</b>",
            "published_date": "2025-02-14T04:56:00Z",
            "discovery_date": "2025-02-15T00:31:53.537321Z",
            "link": "https://clinicaltrials.gov/study/NCT06826638?cond=Multiple+Sclerosis",
            "identifiers": {
                "nct": "NCT06826638",
                "euct": null,
                "eudract": null
            },
            "team_categories": [],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": null,
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": null,
            "intervention": null,
            "primary_outcome": null,
            "secondary_outcome": null,
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5050,
            "title": "Spinal Cord Monitoring in Multiple Sclerosis",
            "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Sponsors</b>: Zuyderland Medisch Centrum\n<br /><b>Recruiting</b>",
            "published_date": "2025-02-14T04:56:00Z",
            "discovery_date": "2025-02-15T00:31:53.435414Z",
            "link": "https://clinicaltrials.gov/study/NCT06827834?cond=Multiple+Sclerosis",
            "identifiers": {
                "nct": "NCT06827834",
                "euct": null,
                "eudract": null
            },
            "team_categories": [],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": null,
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": null,
            "intervention": null,
            "primary_outcome": null,
            "secondary_outcome": null,
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5049,
            "title": "Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study\nPROTOCOL CODE: OZA22 / IM047 - 048",
            "summary": "<b>Trial number</b>: 2024-518859-27-00<br />\n<b>Overall trial status</b>: Ongoing, recruiting<br />\n<b>Trial title</b>: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study\nPROTOCOL CODE: OZA22 / IM047 - 048<br />\n<b>Medical conditions</b>: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)<br />\n<b>Status in each country</b>: Italy:Ongoing, recruiting<br />\n<b>Trial phase</b>: Therapeutic use (Phase IV)<br />\n<b>Therapeutic Areas</b>: Diseases [C] - Nervous System Diseases [C10]<br />\n<b>Primary end point</b>: CSF (and serum) concentration of CXCL13 protein (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12.<br />\n<b>Secondary end point</b>: CSF (and serum) concentration of specific markers of activated meningeal inflammation (CXCL12, TNF-a, IFN-¿) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12., CSF (and serum) concentration of specific makers of activated microglia/macrophages (Chitinase 3-like1, Osteopontin, sCD163, CX3CL1) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12., CSF (and serum) concentration of specific markers of neuronal/axonal damage (neurofilamentlight chains, parvalbumin) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12, Number and volume of cortical lesions measured before starting ozanimod treatment (Prebaseline) and at T12, Number and susceptibility of of paramagnetic rim lesions measured before starting ozanimod treatment (Prebaseline), at baseline (T0) and after 1 year of ozanimod treatment (T12), Variation of the volume of white matter lesions before starting ozanimod treatment (¿ prebaseline-T0) and after 1 year of ozanimod treatment (¿ T0-T12), Variation global and regional cortical thickness change before starting ozanimod treatment (¿prebaseline-T0) and after 1 year of ozanimod treatment (¿ T0-T12), Significant linear relationship between the variation of the above-mentioned cytokines (¿ T0-T12) and the EDSS change (¿ T0-T12) or the relapse number by the end of the follow-up (T12)<br />\n<b>Age of participants</b>: 65+ years, 18-64 years<br />\n<b>Gender of participants</b>: Female, Male<br />\n<b>Trial region</b>: EEA only<br />\n<b>Planned number of participants</b>: 50<br />\n<b>Sponsor</b>: Azienda Ospedaliera Universitaria Integrata Verona<br />\n<b>Sponsor type</b>: Hospital/Clinic/Other health care facility<br />\n<b>Trial product</b>: Zeposia 0.92 mg hard capsules<br />\n<b>Results posted</b>: No<br />\n<b>Overall decision date</b>: 11/11/2024<br />\n<b>Countries decision date</b>: IT: 11/11/2024<br />\n<b>Last updated date</b>: 11/11/2024",
            "published_date": "2025-02-14T00:00:00Z",
            "discovery_date": "2025-02-14T12:32:40.967693Z",
            "link": "https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-518859-27-00",
            "identifiers": {
                "nct": null,
                "euct": "2024-518859-27-00",
                "eudract": null
            },
            "team_categories": [
                {
                    "id": 40,
                    "category_name": "Ozanimod",
                    "category_description": "Ozanimod",
                    "category_slug": "ozanimod",
                    "category_terms": [
                        "ozanimod",
                        "zeposia"
                    ]
                }
            ],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": "Azienda Ospedaliera Universitaria Integrata Verona",
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": "Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)",
            "intervention": null,
            "primary_outcome": "CSF (and serum) concentration of CXCL13 protein (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12.",
            "secondary_outcome": "CSF (and serum) concentration of specific markers of activated meningeal inflammation (CXCL12, TNF-a, IFN-¿) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12., CSF (and serum) concentration of specific makers of activated microglia/macrophages (Chitinase 3-like1, Osteopontin, sCD163, CX3CL1) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12., CSF (and serum) concentration of specific markers of neuronal/axonal damage (neurofilamentlight chains, parvalbumin) (ng/ml/mgPro) measured before starting ozanimod treatment (Prebaseline) and at T12, Number and volume of cortical lesions measured before starting ozanimod treatment (Prebaseline) and at T12, Number and susceptibility of of paramagnetic rim lesions measured before starting ozanimod treatment (Prebaseline), at baseline (T0) and after 1 year of ozanimod treatment (T12), Variation of the volume of white matter lesions before starting ozanimod treatment (¿ prebaseline-T0) and after 1 year of ozanimod treatment (¿ T0-T12), Variation global and regional cortical thickness change before starting ozanimod treatment (¿prebaseline-T0) and after 1 year of ozanimod treatment (¿ T0-T12), Significant linear relationship between the variation of the above-mentioned cytokines (¿ T0-T12) and the EDSS change (¿ T0-T12) or the relapse number by the end of the follow-up (T12)",
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5048,
            "title": "P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)",
            "summary": "<b>Trial number</b>: 2024-514617-35-00<br />\n<b>Overall trial status</b>: Authorised, recruiting<br />\n<b>Trial title</b>: P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)<br />\n<b>Medical conditions</b>: Progressive forms of Multiple Sclerosis<br />\n<b>Status in each country</b>: Germany:Authorised, recruiting, Czechia:Authorised, recruiting, Netherlands:Authorised, recruiting, Bulgaria:Authorised, recruiting, Romania:Authorised, recruiting, Poland:Authorised, recruiting<br />\n<b>Trial phase</b>: Therapeutic exploratory (Phase II)<br />\n<b>Therapeutic Areas</b>: Diseases [C] - Nervous System Diseases [C10]<br />\n<b>Primary end point</b>: Annualized rate of percent brain volume change (PBVC) during MT period.<br />\n<b>Secondary end point</b>: Time to 24-week confirmed disability worsening as assessed on a composite of EDSS, 9-Hole Peg Test (9-HPT), or Timed 25-foot Walk (T25-FW) (24wCDW-Comp) during the MT period<br />\n<b>Age of participants</b>: 18-64 years<br />\n<b>Gender of participants</b>: Female, Male<br />\n<b>Trial region</b>: In both EEA and non-EEA<br />\n<b>Planned number of participants</b>: 230<br />\n<b>Sponsor</b>: Immunic AG<br />\n<b>Sponsor type</b>: Pharmaceutical company<br />\n<b>Trial product</b>: Placebo for IMU-838 Tablets, IMU-838 45 mg tablet, IMU-838 22.5 mg tablet<br />\n<b>Results posted</b>: No<br />\n<b>Overall decision date</b>: 12/09/2024<br />\n<b>Countries decision date</b>: BG: 16/09/2024, CZ: 12/09/2024, DE: 17/09/2024, RO: 25/09/2024, NL: 18/09/2024, PL: 21/10/2024<br />\n<b>Last updated date</b>: 14/02/2025",
            "published_date": "2025-02-15T00:00:00Z",
            "discovery_date": "2025-02-13T12:32:27.862842Z",
            "link": "https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-514617-35-00",
            "identifiers": {
                "nct": null,
                "euct": "2024-514617-35-00",
                "eudract": null
            },
            "team_categories": [
                {
                    "id": 18,
                    "category_name": "IMU-838",
                    "category_description": "Vidofludimus calcium (IMU-838) is a small molecule investigational drug in development as an oral next-generation treatment option for patients with multiple sclerosis, or MS, and other chronic inflammatory and autoimmune diseases.\r\n\r\n\r\n\r\n\r\nsg",
                    "category_slug": "imu-838",
                    "category_terms": [
                        "IMU-838",
                        "vidofludimus calcium",
                        "vidofludimus"
                    ]
                }
            ],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": "Immunic AG",
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": "Progressive forms of Multiple Sclerosis",
            "intervention": null,
            "primary_outcome": "Annualized rate of percent brain volume change (PBVC) during MT period.",
            "secondary_outcome": "Time to 24-week confirmed disability worsening as assessed on a composite of EDSS, 9-Hole Peg Test (9-HPT), or Timed 25-foot Walk (T25-FW) (24wCDW-Comp) during the MT period",
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5047,
            "title": "Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral Istradefylline 40 mg once daily for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)",
            "summary": "<b>Trial number</b>: 2024-517336-21-00<br />\n<b>Overall trial status</b>: Authorised, recruitment pending<br />\n<b>Trial title</b>: Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral Istradefylline 40 mg once daily for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)<br />\n<b>Medical conditions</b>: Progressive multiple sclerosis<br />\n<b>Status in each country</b>: Finland:Authorised, recruitment pending<br />\n<b>Trial phase</b>: Therapeutic exploratory (Phase II)<br />\n<b>Therapeutic Areas</b>: Diseases [C] - Nervous System Diseases [C10], Diseases [C] - Immune System Diseases [C20]<br />\n<b>Primary end point</b>: The change in proportion of active voxels in supratentorial cerebral white matter in the end-of-treatment TSPO-PET images vs. baseline TSPO-PET images in participants with progressive MS treated with istradefylline vs. placebo<br />\n<b>Secondary end point</b>: Change in number of TSPO-PET–measurable chronic active lesions, Change in proportion of TSPO-PET–detectable active voxels at the rim of chronic lesions (change in proportion of active voxels), Change in proportion of TSPO-PET–detectable active voxels in the NAWM (change in proportion of active voxels), Change in TSPO-PET signal (DVR, distribution volume ratio) at the rim of chronic lesions, Change in DVR in the NAWM, Change in QSM-positive iron rim lesions, Change in MRI volumetric measures in the brain regions of interest, Change in T1 and T2 lesion burden using MRI, Change in neuroaxonal damage measured by DTI-MRI parameters, Change in disease worsening measured using the Timed 25 Foot Walk, Change in hand dexterity measured using the 9-Hole Peg Test, Change in functional Systems and Expanded Disability Status Scale, Change in cognition measured using neuropsychological evaluation, Change in health-related quality of life measured using the RAND 36-Item Health Survey and Multiple Sclerosis Impact Scale questionnaires, Change in fatigue measured using the Modified Fatigue Impact Scale and Fatigue Severity Scale questionnaires, Change in blood serum neurofilament light chain and glial fibrillary acdic protein levels<br />\n<b>Age of participants</b>: 18-64 years<br />\n<b>Gender of participants</b>: Female, Male<br />\n<b>Trial region</b>: EEA only<br />\n<b>Planned number of participants</b>: 34<br />\n<b>Sponsor</b>: University Of Turku<br />\n<b>Sponsor type</b>: Educational Institution<br />\n<b>Trial product</b>: Placebo tablets will be white, round, flat, scored tablet, 9 mm in diameter sourced from Yliopiston Apteekki, ISTRADEFYLLINE<br />\n<b>Results posted</b>: No<br />\n<b>Overall decision date</b>: 15/11/2024<br />\n<b>Countries decision date</b>: FI: 15/11/2024<br />\n<b>Last updated date</b>: 12/02/2025",
            "published_date": "2025-02-13T00:00:00Z",
            "discovery_date": "2025-02-13T12:32:27.318863Z",
            "link": "https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-517336-21-00",
            "identifiers": {
                "nct": null,
                "euct": "2024-517336-21-00",
                "eudract": null
            },
            "team_categories": [],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": "University Of Turku",
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": "Progressive multiple sclerosis",
            "intervention": null,
            "primary_outcome": "The change in proportion of active voxels in supratentorial cerebral white matter in the end-of-treatment TSPO-PET images vs. baseline TSPO-PET images in participants with progressive MS treated with istradefylline vs. placebo",
            "secondary_outcome": "Change in number of TSPO-PET–measurable chronic active lesions, Change in proportion of TSPO-PET–detectable active voxels at the rim of chronic lesions (change in proportion of active voxels), Change in proportion of TSPO-PET–detectable active voxels in the NAWM (change in proportion of active voxels), Change in TSPO-PET signal (DVR, distribution volume ratio) at the rim of chronic lesions, Change in DVR in the NAWM, Change in QSM-positive iron rim lesions, Change in MRI volumetric measures in the brain regions of interest, Change in T1 and T2 lesion burden using MRI, Change in neuroaxonal damage measured by DTI-MRI parameters, Change in disease worsening measured using the Timed 25 Foot Walk, Change in hand dexterity measured using the 9-Hole Peg Test, Change in functional Systems and Expanded Disability Status Scale, Change in cognition measured using neuropsychological evaluation, Change in health-related quality of life measured using the RAND 36-Item Health Survey and Multiple Sclerosis Impact Scale questionnaires, Change in fatigue measured using the Modified Fatigue Impact Scale and Fatigue Severity Scale questionnaires, Change in blood serum neurofilament light chain and glial fibrillary acdic protein levels",
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5046,
            "title": "Noninvasive Vagal Nerve Stimulation",
            "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Device: Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS); Device: Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS); Device: Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)\n<br /><b>Sponsors</b>: NYU Langone Health\n<br /><b>Recruiting</b>",
            "published_date": "2025-02-10T04:56:00Z",
            "discovery_date": "2025-02-12T00:30:28.842994Z",
            "link": "https://clinicaltrials.gov/study/NCT06816004?cond=Multiple+Sclerosis",
            "identifiers": {
                "nct": "NCT06816004",
                "euct": null,
                "eudract": null
            },
            "team_categories": [],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": null,
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": null,
            "intervention": null,
            "primary_outcome": null,
            "secondary_outcome": null,
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5045,
            "title": "Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation",
            "summary": "<b>Conditions</b>: Rehabilitation; Multiple Sclerosis; Cognitive Deficit; Motor Deficits\n<br /><b>Interventions</b>: Device: Cognitive rehabilitation: CG group; Device: Motor rehabilitation: MG group; Device: Combined rehabilitation: CbG group\n<br /><b>Sponsors</b>: Universita di Verona\n<br /><b>Recruiting</b>",
            "published_date": "2025-02-11T04:56:00Z",
            "discovery_date": "2025-02-12T00:30:28.728933Z",
            "link": "https://clinicaltrials.gov/study/NCT06820125?cond=Multiple+Sclerosis",
            "identifiers": {
                "nct": "NCT06820125",
                "euct": null,
                "eudract": null
            },
            "team_categories": [],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": null,
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": null,
            "intervention": null,
            "primary_outcome": null,
            "secondary_outcome": null,
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5044,
            "title": "A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis",
            "summary": "<b>Trial number</b>: 2023-506516-40-00<br />\n<b>Overall trial status</b>: Ongoing, recruitment ended<br />\n<b>Trial title</b>: A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis<br />\n<b>Medical conditions</b>: Relapsing-Remitting Multiple Sclerosis<br />\n<b>Status in each country</b>: Belgium:Ongoing, recruitment ended, Romania:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Netherlands:Ended, Denmark:Ended, Estonia:Ongoing, recruitment ended, Austria:Ongoing, recruitment ended, Croatia:Ended, Hungary:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended, Bulgaria:Ended, Spain:Ongoing, recruitment ended, Latvia:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended<br />\n<b>Trial phase</b>: Therapeutic confirmatory  (Phase III)<br />\n<b>Therapeutic Areas</b>: Diseases [C] - Nervous System Diseases [C10]<br />\n<b>Primary end point</b>: 1. Protocol-defined annualized relapse rate (ARR) (non-inferiority)<br />\n<b>Secondary end point</b>: 1. Number of new or enlarging T2 lesions as detected by brain MRI during the double-blind period, 2. Number of T1 gadolinium (Gd) lesions at Week 12, 3. Protocol-defined ARR during the double-blind period (superiority), 4. Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), 5. Change from baseline in targeted vital signs and clinical significant abnormalities in electrocardiogram (ECG) parameters, 6. Change from baseline in targeted clinical laboratory test results, 7. Concentrations of ocrelizumab at indicated time points, 8. Levels of CD19 B-cell count in blood, 9. Prevalence of anti-drug antibodies (ADAs) against ocrelizumab at baseline, 10. Incidence of ADAs against ocrelizumab during the study<br />\n<b>Age of participants</b>: 0-17 years<br />\n<b>Gender of participants</b>: Female, Male<br />\n<b>Trial region</b>: In both EEA and non-EEA<br />\n<b>Planned number of participants</b>: 94<br />\n<b>Sponsor</b>: F. Hoffmann-La Roche AG<br />\n<b>Sponsor type</b>: Pharmaceutical company<br />\n<b>Trial product</b>: Gilenya 0.25 mg hard capsules, Placebo for Ocrelizumab, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Reisetabletten AL\nDimenhydrinat 50 mg pro Tablette, Gilenya 0.5 mg hard capsules, Placebo for FINGOLIMOD, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Gilenya 0.25 mg hard capsules<br />\n<b>Results posted</b>: No<br />\n<b>Overall decision date</b>: 07/02/2024<br />\n<b>Countries decision date</b>: AT: 25/03/2024, PL: 20/02/2024, IT: 12/02/2024, DE: 09/02/2024, LV: 07/02/2024, RO: 12/02/2024, ES: 08/02/2024, NL: 08/02/2024, BG: 18/03/2024, PT: 07/02/2024, BE: 14/02/2024, HU: 08/02/2024, FR: 16/02/2024, DK: 07/02/2024, HR: 08/02/2024, EE: 12/02/2024, GR: 22/03/2024<br />\n<b>Last updated date</b>: 14/02/2025",
            "published_date": "2025-02-15T00:00:00Z",
            "discovery_date": "2025-02-11T12:31:39.986896Z",
            "link": "https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-506516-40-00",
            "identifiers": {
                "nct": null,
                "euct": "2023-506516-40-00",
                "eudract": null
            },
            "team_categories": [
                {
                    "id": 6,
                    "category_name": "Ocrelizumab",
                    "category_description": "",
                    "category_slug": "ocrelizumab",
                    "category_terms": [
                        "ocrelizumab",
                        "ocrevus"
                    ]
                },
                {
                    "id": 35,
                    "category_name": "Fingolimod",
                    "category_description": "Fingolimod, also known as Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/gilenya",
                    "category_slug": "fingolimod",
                    "category_terms": [
                        "fingolimod",
                        "gilenya"
                    ]
                }
            ],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": "F. Hoffmann-La Roche AG",
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": "Relapsing-Remitting Multiple Sclerosis",
            "intervention": null,
            "primary_outcome": "1. Protocol-defined annualized relapse rate (ARR) (non-inferiority)",
            "secondary_outcome": "1. Number of new or enlarging T2 lesions as detected by brain MRI during the double-blind period, 2. Number of T1 gadolinium (Gd) lesions at Week 12, 3. Protocol-defined ARR during the double-blind period (superiority), 4. Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), 5. Change from baseline in targeted vital signs and clinical significant abnormalities in electrocardiogram (ECG) parameters, 6. Change from baseline in targeted clinical laboratory test results, 7. Concentrations of ocrelizumab at indicated time points, 8. Levels of CD19 B-cell count in blood, 9. Prevalence of anti-drug antibodies (ADAs) against ocrelizumab at baseline, 10. Incidence of ADAs against ocrelizumab during the study",
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5043,
            "title": "The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study",
            "summary": "<b>Conditions</b>: Multiple Sclerosis (MS) - Relapsing-remitting\n<br /><b>Interventions</b>: Drug: Metformin (Cidophage®); Other: Usual Care\n<br /><b>Sponsors</b>: German University in Cairo\n<br /><b>Completed</b>",
            "published_date": "2025-02-06T04:56:00Z",
            "discovery_date": "2025-02-07T00:30:05.292574Z",
            "link": "https://clinicaltrials.gov/study/NCT06812585?cond=Multiple+Sclerosis",
            "identifiers": {
                "nct": "NCT06812585",
                "euct": null,
                "eudract": null
            },
            "team_categories": [
                {
                    "id": 4,
                    "category_name": "Metformin",
                    "category_description": "",
                    "category_slug": "metformin",
                    "category_terms": [
                        "metformin"
                    ]
                }
            ],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": null,
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": null,
            "intervention": null,
            "primary_outcome": null,
            "secondary_outcome": null,
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 5042,
            "title": "A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension",
            "summary": "<b>Trial number</b>: 2024-511686-11-00<br />\n<b>Overall trial status</b>: Ongoing, recruitment ended<br />\n<b>Trial title</b>: A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension<br />\n<b>Medical conditions</b>: Multiple Sclerosis in pediatric patients<br />\n<b>Status in each country</b>: Croatia:Ongoing, recruitment ended, Romania:Authorised, recruitment pending, Austria:Ongoing, recruitment ended, Estonia:Ongoing, recruitment ended, Latvia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Portugal:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, France:Ongoing, recruitment ended<br />\n<b>Trial phase</b>: Therapeutic confirmatory  (Phase III)<br />\n<b>Therapeutic Areas</b>: Diseases [C] - Nervous System Diseases [C10]<br />\n<b>Primary end point</b>: Annualized relapse rate (ARR of confirmed relapses)<br />\n<b>Secondary end point</b>: Annualized relapse rate (ARR of confirmed relapses), Number of new or newly enlarging T2 lesions on MRI per year (annualized T2 lesion rate), Neurofilament light chain (NfL) concentration in serum, Ofatumumab and siponimod and (metabolite M17) plasma concentrations, Proportion of participants with anti-ofatumumab antibodies, Adverse events, Columbia Suicide Severity Rating Scale (C-SSRS), ECG, laboratory and ophthalmological data, pulmonary function tests and vital signs<br />\n<b>Age of participants</b>: 0-17 years<br />\n<b>Gender of participants</b>: Female, Male<br />\n<b>Trial region</b>: In both EEA and non-EEA<br />\n<b>Planned number of participants</b>: 62<br />\n<b>Sponsor</b>: Novartis Pharma AG<br />\n<b>Sponsor type</b>: Pharmaceutical company<br />\n<b>Trial product</b>: BAF312, BAF312, BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB<br />\n<b>Results posted</b>: No<br />\n<b>Overall decision date</b>: 09/07/2024<br />\n<b>Countries decision date</b>: PT: 10/07/2024, ES: 10/07/2024, EE: 15/07/2024, BE: 09/07/2024, PL: 18/07/2024, DE: 12/07/2024, IT: 15/07/2024, LV: 09/07/2024, HR: 09/07/2024, SK: 09/07/2024, RO: 11/07/2024, AT: 15/07/2024, FR: 11/07/2024<br />\n<b>Last updated date</b>: 06/02/2025",
            "published_date": "2025-02-07T00:00:00Z",
            "discovery_date": "2025-02-06T12:33:19.137050Z",
            "link": "https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-511686-11-00",
            "identifiers": {
                "nct": null,
                "euct": "2024-511686-11-00",
                "eudract": null
            },
            "team_categories": [
                {
                    "id": 10,
                    "category_name": "Siponimod",
                    "category_description": "Siponimod (also known as BAF312 or Mayzent) is a tablet being developed for secondary progressive MS by Novartis Pharmaceuticals. It was licensed by the European Medicines Agency (EMA) on Monday 20 January 2020.\n\nhttps://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/explore-treatments-in-trials/siponimod",
                    "category_slug": "siponimod",
                    "category_terms": [
                        "siponimod",
                        "BAF312",
                        "Mayzent"
                    ]
                },
                {
                    "id": 29,
                    "category_name": "Ofatumumab",
                    "category_description": "ofatumumab, Kesimpta",
                    "category_slug": "ofatumumab",
                    "category_terms": [
                        "ofatumumab",
                        "kesimpta"
                    ]
                },
                {
                    "id": 35,
                    "category_name": "Fingolimod",
                    "category_description": "Fingolimod, also known as Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/gilenya",
                    "category_slug": "fingolimod",
                    "category_terms": [
                        "fingolimod",
                        "gilenya"
                    ]
                }
            ],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": "Novartis Pharma AG",
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis in pediatric patients",
            "intervention": null,
            "primary_outcome": "Annualized relapse rate (ARR of confirmed relapses)",
            "secondary_outcome": "Annualized relapse rate (ARR of confirmed relapses), Number of new or newly enlarging T2 lesions on MRI per year (annualized T2 lesion rate), Neurofilament light chain (NfL) concentration in serum, Ofatumumab and siponimod and (metabolite M17) plasma concentrations, Proportion of participants with anti-ofatumumab antibodies, Adverse events, Columbia Suicide Severity Rating Scale (C-SSRS), ECG, laboratory and ophthalmological data, pulmonary function tests and vital signs",
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        }
    ]
}